Trajan Group has updated investors that market demand for its analytical science and device products remained broadly in line with expectations during the second half of financial year 2026 and that the business continues to grow on a fixed foreign exchange basis.

Neurizon Therapeutics has announced that Regimen I of the HEALEY ALS Platform Trial will grow from 160 participants to 240, a decision the company attributed to faster-than-expected enrolment and the absence of a concurrent regimen during the recruitment window.

The licence would cover the Kingdom of Saudi Arabia, the Gulf Cooperation Council countries and key North African markets, including Egypt, Algeria and Morocco, while Recce would remain responsible for manufacture and supply.

The company said it has now developed oligonucleotides that can greatly amplify TLR8 activity compared with current best-in-class drugs in clinical development, which could in turn enhance the cancer-fighting activity of standard-of-care therapies such as chemotherapy and radiotherapy.

Imugene has released Phase 1b data that show promising activity for its off-the-shelf allogeneic CAR T therapy Azer-cel in patients with relapsed or refractory B-cell malignancies who had not previously received autologous CAR T treatment.

Percheron Therapeutics (ASX:PER) has announced that the World Health Organization has selected 'minperstobart' as the proposed international nonproprietary name for its investigational cancer therapy HMBD-002.

NeuroScientific Biopharmaceuticals has reported significant outcomes from its Special Access Program treating fistulising Crohn’s disease with the company's StemSmart mesenchymal stem cell therapy.

Vitrafy Managing Director and CEO Brent Owens added, "The final Phase II report from USAISR delivers independent validation that our decentralised, no-wash platelet preservation platform exceeds regulatory and quality guidelines on every meaningful measure."

Avecho Biotechnology has announced that it has completed the treatment phase for the final patient needed for the planned interim analysis of its pivotal Phase 3 insomnia trial.

Australian innovators are addressing pressing health challenges worldwide and securing pharmaceutical patents at levels comparable to those of Israel and Switzerland.

The material will be presented by CSL at the Options for the Control of Influenza XIII Conference in August in Washington, DC, and will relate to how Noxopharm’s novel oligonucleotides from its Sofra technology platform could be used to improve the delivery of self-amplifying mRNA vaccines.

Nyrada has reported that its lead drug candidate Xolatryp demonstrated clear anti-tumour activity in a rodent model of liver cancer, both alone and in combination with the anthracycline chemotherapy doxorubicin.

OncoSil Medical has secured approval from the Australian Therapeutic Goods Administration for its OncoSil device to be used alongside gemcitabine-based chemotherapy for patients with unresectable locally advanced pancreatic cancer.

Patrys has taken a step toward clinical-stage development of its RLS-2202 program by appointing CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the contract research organisation to manage the study.

Cleo Diagnostics has outlined the first stage of its United States commercialisation and reimbursement plan for its Pre‑Surgical Ovarian Cancer Test as it moves toward anticipated FDA clearance.

Leaders from Australia’s medical technology sector have gathered in Perth for AusMedtech 2026 to explore innovation, translation and commercialisation across the medtech ecosystem.

AusBiotech Invest Perth 2026 will open its doors in Perth today, bringing together investors, life sciences companies, and global partners focused on the next generation of breakthroughs.